Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ)

CAPS Rating: 3 out of 5

A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Results 1 - 20 of 44 : 1 2 3 Next »

Recs

0
Member Avatar 1badbeerad (45.41) Submitted: 6/9/2014 2:40:37 AM : Outperform Start Price: $146.90 JAZZ Score: -4.12

Is one to watch and ride.

Recs

0
Member Avatar McRCN (44.02) Submitted: 4/4/2014 5:51:28 PM : Outperform Start Price: $127.13 JAZZ Score: +5.74

buy on pull back.

Recs

0
Member Avatar tdoodler (24.52) Submitted: 3/13/2014 2:23:27 PM : Underperform Start Price: $149.32 JAZZ Score: +11.32

breaks support

Recs

0
Member Avatar DugdaleTiki (39.42) Submitted: 3/3/2014 9:25:10 AM : Outperform Start Price: $147.28 JAZZ Score: -10.29

2014 Sabrient Pick

Recs

0
Member Avatar TerryFool (< 20) Submitted: 2/16/2014 12:58:08 PM : Outperform Start Price: $146.90 JAZZ Score: -10.01

Long term invest, 3YR REV 65% 3YR EPS 100%, TP $200

Recs

0
Member Avatar 1picks (84.72) Submitted: 1/13/2014 2:24:18 PM : Outperform Start Price: $147.27 JAZZ Score: -11.63

Sabrient

Recs

0
Member Avatar exoblight (< 20) Submitted: 1/4/2014 12:39:20 PM : Outperform Start Price: $127.00 JAZZ Score: +4.45

Gentium acquisition likely to improve bottom line

Recs

0
Member Avatar SqwiiTrader (50.32) Submitted: 12/13/2013 3:53:00 AM : Underperform Start Price: $115.91 JAZZ Score: -12.18

bearish engulfing

Recs

1
Member Avatar grankh (75.20) Submitted: 10/21/2013 1:08:23 AM : Outperform Start Price: $82.98 JAZZ Score: +56.36

Another stock I own personally.

Sales have grown 80% per year on average since 2010. EPS has grown 56% over the past 18 months. The profit margin has fluctuated considerably, so not joy there. The earned-on-equity has fallen in each of the past 2 years, so the wrong trend. Debt has fluctuated also, though is generally down over the past 3 years. The P/E is above its recent average, but lower than it reached in 2010 and 2011, so not unreasonable, (though its earned-on-equity was much higher in those years, so the higher P/E was justified). The PEG ratio is attractive. The company does NOT pay a dividend, so sadness in that area. I mainly bought this stock due to the rapid growth in Sales and EPS, so see if the stock can continue its rapid, upward trajectory.

Even assuming a growth rate at less than half what the company has been growing at over the past few years, I think this stock could gain 16% or more annually for the next 5 years. However, if its earned-on-equity keeps falling, I may revisit this holding to see if I think it can still grow for me at the rate I want it to, especially since it will not pay me a dividend to offset any potential downside due to the lower earnings growth rate. So one to keep an eye on, and hope the growth rates are maintained for a while longer.

Recs

0
Member Avatar talkingdog (89.57) Submitted: 9/26/2013 7:55:22 AM : Outperform Start Price: $88.39 JAZZ Score: +44.46

underpriced?

Recs

0
Member Avatar awallejr (83.92) Submitted: 9/11/2013 8:15:09 PM : Outperform Start Price: $86.01 JAZZ Score: +48.93

Heard about this stock on Pimm Fox's radio show. Kind of wish I heard about it a year ago. Despite its run up it still looks cheap.

Recs

0
Member Avatar chris293 (84.53) Submitted: 9/11/2013 8:12:17 PM : Outperform Start Price: $86.01 JAZZ Score: +48.93

This sounds like the drug company of choice for people with any number of problems.

Recs

0
Member Avatar onecandream (85.30) Submitted: 9/2/2013 11:07:20 AM : Outperform Start Price: $88.95 JAZZ Score: +40.55

IBD 50

Recs

0
Member Avatar s2dbaker (90.07) Submitted: 8/2/2013 6:07:25 AM : Outperform Start Price: $76.50 JAZZ Score: +70.17

Le Jazz Hot!

Recs

0
Member Avatar manirg (57.24) Submitted: 7/30/2013 6:20:40 PM : Outperform Start Price: $75.03 JAZZ Score: +72.90

very undervalued

Recs

0
Member Avatar 1russianguy (61.14) Submitted: 6/20/2013 3:06:54 PM : Outperform Start Price: $65.00 JAZZ Score: +95.48

screen

Recs

0
Member Avatar Pops61 (53.03) Submitted: 3/12/2013 1:41:20 AM : Outperform Start Price: $59.91 JAZZ Score: +111.06

Several drugs for mental illness and non-opiod pain management. Sold under performing subsidiary in June 2012. Fwd P/E 9.26. Upgrade with Target price 87.10.

Recs

0
Member Avatar callumturcan (97.43) Submitted: 2/26/2013 2:36:34 PM : Outperform Start Price: $56.64 JAZZ Score: +119.73

Lots of growth at a cheap valuation

Recs

0
Member Avatar TerryHoodSr (51.53) Submitted: 1/4/2013 8:27:17 PM : Outperform Start Price: $55.21 JAZZ Score: +122.56

hold it

Recs

1
Member Avatar LocalLegend (98.24) Submitted: 1/3/2013 2:12:47 PM : Outperform Start Price: $54.81 JAZZ Score: +124.57

JAZZ has had a great year, up approximately 41.44%, the good news is there is still room for growth.

- Based on 10 analysts offering Price Targets the Median is $70, which is 25% higher than its Last Price $56, a High Target of $81 (+44.64%), and a Low Target of $60 still represents a 7.14% premium.
- In the current month, 7 analysts recommend Strong Buy and 5 Buy
- JAZZ is valued at a discount with a PEG value of 0.85, one of the lowest in the Biotechnology & Drugs industry.
- The company converts a larger percentage of revenues to profits than most in the industry, with an Operating Margin of 34.58%
- Consistently one of the most efficient companies in the Biotechnology & Drugs industry, with a Return on Assets of 13.69% (Industry Avg 4.78%), Revenue Per Employee $1,127,174 (Industry Avg $729,054), and Return on Equity 25.78% (Industry Avg 11.46%)
- Debt to Total Capital Ratio in line with Industry Avg

Recommendation: I am long JAZZ with a Price Target of $72.00

Results 1 - 20 of 44 : 1 2 3 Next »

Featured Broker Partners


Advertisement